Abstract
Many anticancer drugs and environmental carcinogens exert cytotoxic and or mutagenic effects through the direct reaction with DNA via in the formation of drug-DNA adducts or stabilized protein-DNA complexes (1,2). The ability to determine the extent with which drugs, such as alkylating agents and platinum based drugs, interact with their cellular targets in tumor cells will permit further studies into cytotoxic and biological effects of these drugs. The use of antisera or antibodies directed against specific adducts has facilitated the development of immunologically based assays, such as ELISA methods, to determine the extent of drug-DNA interaction in cells. These techniques however, rely on the measurement of adducts on DNA isolated from millions of cells (described by Tilby in Chapter 12 and refs. 3 and 4).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Lawley, P. D. and Phillips, D. H. (1996) DNA adducts from chemotherapeutic agents. Mutation Res. 355, 13–40.
Kohn, K. W. (1996) Beyond DNA cross-linking: history and prospects of DNA-targeted cancer treatment. 15th Bruce F. Cain Memorial Award Lecture. Cancer Res. 56, 5533–5546.
Tilby, M. J., Styles, J. M., and Dean, C. J. (1987) Immunological detection of DNA damage caused by melphalan using monoclonal antibodies. Cancer Res. 47, 1542–1546.
Tilby, M. J., Newell, D. R., Viner, C., Selby, P. J., and Dean, C. J. (1993) Application of a sensitive immunoassay to the study of DNA adducts formed in peripheral blood mononuclear cells of patients undergoing high-dose melphalan therapy. Eur. J. Cancer 29A(5), 681–686.
Den Engelse, L., Van Benthem, J., and Scherer, E. (1990) Immunolocytochemical analysis of in vivo DNA modifications. Mutation Res. 233, 265–287.
Blommaert, F. A., Michael, C., Terheggen, P. M. A. B., Muggiam, F. M., Kortes, V., Chomagel, J. H., Hart, A. A. M., and Den Engelse, L. (1993) Drug-induced DNA modification of buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: inter-individual variation and correlation with disease response. Cancer Res. 53, 5669.
Motykiewic, z G., Malusecka, E., Grzybowska, E., Chorazy, M., Zhang, Y.-J., Perera, F. P., and Santella, R. M. (1995) Immunohistochemical quantification of polycyclic aromatic hydrocarbon-DNA adducts in human lymphocytes. Cancer Res. 55, 1417.
Seiler, F., Kirstein, U., Eberle, G., Hochleitner, K., and Rajewsky, M. F. (1993) Quantification of specific DNA-alkylation products in individual cells by monoclonal antibodies and digital imaging of intensified nuclear fluorescence. Carcinogenesis 14, 1907.
Frank, A. J., Proctor, S. J., and Tilby, M. J. (1996) Detection and quantification of melphalan-DNA adducts at the single cell level in hemopoietic tumor cells. Blood 88(3), 977–984.
Haugland, R. P. (1997) Handbook of Fluorescence Probes and Research Chemicals. Molecular Probes, Inc., pp. 608–614.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Humana Press Inc.
About this protocol
Cite this protocol
Frank, A.J. (1999). Measuring Drug-DNA Adducts in Individual Cells. In: Brown, R., Böger-Brown, U. (eds) Cytotoxic Drug Resistance Mechanisms. Methods in Molecular Medicine™, vol 28. Humana Press. https://doi.org/10.1385/1-59259-687-8:129
Download citation
DOI: https://doi.org/10.1385/1-59259-687-8:129
Publisher Name: Humana Press
Print ISBN: 978-0-89603-603-1
Online ISBN: 978-1-59259-687-4
eBook Packages: Springer Protocols